News | January 20, 2022
Green chemistry approaches to synthesis could make a big difference to pharma product outputs
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
The company operates in over eight cities and the start-up plans to expand its reach to over 100 non-metro cities in the next 18-24 months
The focus is on wellness and personal care products
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Favipiravir is close to Remdesivir, Remdesivir is used to treat moderate to severe cases while Favipiravir is used to treat mild to moderate cases
Subscribe To Our Newsletter & Stay Updated
